麻豆传媒

These are people who are getting tested and seeing doctors, but still not getting diagnosed

Risk was significantly higher regardless of dialysis status

Of those who do, 88% reported using the gold-standard imaging biomarker in determining prognosis

However, the FDA remains unconvinced that results support a new indication for the drug

Reduced 24-hour UPCR by 38.3%

But researcher questions if patients were underdosed

More research from the National Kidney Foundation Spring Clinical Meeting

Interim PROTECT data show nephroprotective potential of sparsentan

If finerenone isn't available, try spironolactone, said researcher

Consider adding a potassium binder to the mix, researcher suggests

Analysis looked at patients with stage 1-3 CKD from the MIRROR trial

Goal of 30% reduction in serum creatinine in the absence of full response or HRS reversal

Temporary vascular access, uncontrolled hypertension may be risk factors in this population

A round-up of noteworthy research from the NKF Spring Clinical Meetings